News for ChromaDex Corporation (CDXC)

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus o

[url="]ChromaDex Corp.[/url] (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, toda

ChromaDex reports 37.41% revenue growth with Niagen leading success, despite risks, its e-commerce surge and profits signal potential. Read more here.

Operator: Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's Fourth Quarter of 2024 Earnings Conference Call.

The following slide deck was published by ChromaDex Corporation in conjunction with their 2024 Q4 earnings call.

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ETCompany ParticipantsBen Shamsian - Vice President, Lytham...

ChromaDex (CDXC) delivered earnings and revenue surprises of 50% and 7.47%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, w

[url="]ChromaDex Corp. [/url](NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.

If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

[url="]ChromaDex Corp[/url]. (NASDAQ:CDXC) proudly announces its inclusion on the [url="]Inc. 2024 Best in Business[/url] list in the Health Products category.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday. Shares of Cassava Sciences, Inc. SAVA fell sharply in...

Chromadex CFO Pamir Ozan acquires $21,396 in company stock

Shares of Uxin Limited UXIN rose sharply in today's pre-market trading after the company reported second-quarter financial results. Uxin posted quarterly sales...

ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ChromaDex (CDXC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out.

ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.